FDA Issues Draft Guidance for Early Solid Tumor Trials

The FDA has issued draft recommendations for early-phase studies of investigational drugs and biologics targeting solid tumors. The document addresses eligibility, dose escalation, study expansion, activity measures and companion diagnostics, with comments open until 11 January 2027.